25 January 2022
Green Cross Health (NZX:GXH) is currently experiencing higher than anticipated revenue and profitability relative to the prior period. For the 9 months to 31 December 2021, the company has experienced an increase in revenue of approximately 14%.
Group CEO Rachael Newfield said “This uplift is primarily the result of increased COVID-19 related activity across the company’s three divisions of Medical, Pharmacy and Community Health as well as the impact of recent acquisitions in the Medical division. The company notes that this uplift may not continue in full into the next financial year due to the uncertain and changeable outlook for COVID-19 vaccination and swabbing activity”.
Whilst Omicron has introduced further uncertainty, Net Profit After Tax Attributable to Shareholders for the 12 months to 31 March 2022 is projected to exceed the prior period result by $4.5m - $6.5m*. Green Cross Health is scheduled to release its audited full year result for the year to 31 March 2022 on 27 May 2022.
* $5.5m - $7.5m excluding one-off and extraordinary amounts.
About Green Cross Health
Green Cross Health (NZX: GXH) is a trusted New Zealand primary healthcare provider with multidisciplinary healthcare teams with the purpose of working together to support healthier communities. New Zealand owned and operated, Green Cross Health operates under branded groups Unichem and Life Pharmacies, The Doctors medical centres, Total Care Health community nursing services and Access Community Health to provide support, care and advice to diverse New Zealand communities.
The zero-brokerage fee share trading platform is looking for ways to bring in revenue and make its business model more sustainable.
Fletcher Building achieved second-half profit margins of 9.5%, just below its target of 10% by the 2023 financial year.
Even under a “bear-case scenario”, the house building pipeline should support Fletcher’s medium-to-long-term performance.
Trading volumes were unusually light, with US markets closed tonight for a national holiday.
The shareholder representatives say the Fletcher board must bear ultimate responsibility for the company’s poor performance and the Gib plasterboard shortage.
NZME has only spent $5.3m of the $30m set aside for share buybacks.
Are banks being too slow to raise term deposit rates? Some analysts say yes.
Peter McIntyre, an investment adviser at Craigs Investment Partners, says New Zealand’s market has been "reliably well-behaved over the course of the day".
The firm has doubled its headcount and is looking to raise capital to expand its manufacturing and engineering focus into green hydrogen applications.
Meridian says the fact that Australia's electricity market has turned into a train wreck shows its decision to pull out was the right one.
The Ministry for Primary Industries estimated Fonterra’s restructuring would cost the average farmer between $135,000 and $400,000.
New Zealand's biggest transport operator plans to have its first 10 dual-fuel hydrogen trucks on the road next year.
Oanda market analyst Edward Moya said the absence of a Bitcoin rally could be a troubling sign for some investors.
Sky TV and MediaWorks will be brushing themselves off after a bruising response to their proposal scotched a SkyWorks deal.
It's important that constraints remain on Fonterra that counterbalance its privileged position in the dairy sector and the national economy, says TDB Advisory.